Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a note issued to investors on Tuesday. They presently have a $262.00 price objective on the biopharmaceutical company’s stock. Jefferies Group’s price target suggests a potential upside of 28.78% from the company’s previous close.

SHPG has been the topic of a number of other research reports. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Zacks Investment Research lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, June 8th. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 14th. Sanford C. Bernstein reiterated an “outperform” rating and set a $222.00 price objective on shares of Shire PLC in a research note on Thursday, June 9th. Finally, Leerink Swann reiterated a “buy” rating and set a $213.00 price objective (down previously from $225.00) on shares of Shire PLC in a research note on Thursday, June 16th. Four analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $230.67.

Shares of Shire PLC (NASDAQ:SHPG) opened at 203.44 on Tuesday. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The company has a 50-day moving average of $195.66 and a 200 day moving average of $183.51. The stock has a market cap of $60.60 billion, a P/E ratio of 42.28 and a beta of 1.11.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/shire-plc-shpg-given-buy-rating-at-jefferies-group.html

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.35. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The business’s quarterly revenue was up 55.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.63 earnings per share. Equities research analysts forecast that Shire PLC will post $12.93 EPS for the current fiscal year.

The firm also recently declared a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be given a $0.139 dividend. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.

A number of large investors have recently modified their holdings of the company. FTB Advisors Inc. boosted its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Shire PLC by 5.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,728 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 82 shares during the period. Baldwin Investment Management LLC boosted its stake in shares of Shire PLC by 5.1% in the second quarter. Baldwin Investment Management LLC now owns 1,703 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 82 shares during the period. Raymond James Trust N.A. boosted its stake in shares of Shire PLC by 4.6% in the first quarter. Raymond James Trust N.A. now owns 2,591 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 114 shares during the period. Finally, Cohen Klingenstein LLC boosted its stake in shares of Shire PLC by 2.1% in the second quarter. Cohen Klingenstein LLC now owns 5,566 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 117 shares during the period. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.